A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

Kepler Capital analyst Justine Telliez maintained a Buy rating on Valneva (0OB3 – Research Report) on September 18 and set a price ...

Valneva SE (VALN) said that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to ...

Valneva SE (NASDAQ:VALN) and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 ...

Nearly half a million Americans received an unpleasant surprise this summer, according to insurance billing data: a new ...

The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.

Valneva and Pfizer have reported positive data from a Phase II trial of a second booster dose of their Lyme disease vaccine ...

Valneva and Pfizer have reported positive Phase II results for a second booster dose of their vaccine candidate for Lyme ...

A single dose of chikungunya vaccine is safe, effective, provides protection up to 2 years, and does not result in any long-term serious AEs related to vaccination.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).

At the end of June 2024, the Company’s debt amounted to $200 million. Reimbursements of the first $100 million tranche will start in January 2026 and mature in the first quarter of 2027.